PE-owned IMS Health raises $1.3 bln for IPO

By Iris Dorbian — 2 years ago

IMS Health has launched its IPO of 65 million shares after pricing it at $20 per share. The stock began trading Friday on the NYSE under the ticker symbol “IMS.” J.P. Morgan Securities, Goldman Sachs and Morgan Stanley & Co. are the lead underwriters. Headquartered in Danbury, Conn., IMS Health is a global information and technology services firm that focuses on the healthcare sector. It is owned by TPG Capital, CPP Investment Board and Leonard Green & Partners.

Continue

Slideshow: A Look At How Mega-Funds Perform For CalSTRS

By Angela Sormani — 3 years ago

European powerhouse CVC Capital Partners takes the crown in this week’s battle of the U.S. and European mega-buyout houses, securing first place in our list of top 10 funds based on private equity performance figures from California State Teachers’ Retirement System. U.S. and European firms both account for five of the top-10 spots with The Blackstone Group coming in a close second place.

Continue

Slideshow: The Year’s Top Private Equity Deals

By Luisa Beltran — 3 years ago

Last week, we discovered which private equity firm was the biggest dealmaker. Now it’s time for the largest PE deals of the year. Global PE-backed M&A totaled $267 billion so far in 2012, a 12% drop from 2011, according to preliminary data from Thomson Reuters. Private equity-backed mergers targeting the U.S. reached roughly $137 billion year-to-date, a 7% decline from 2011.

Continue

BC Partners and CPPIB in Suddenlink MBO

By Angela Sormani — 4 years ago

BC Partners, CPP Investment Board and management are to acquire Cequel Communications, which does business as Suddenlink Communications, for $6.6 billion. Suddenlink is a cable system operator in the US offering television, high-speed Internet and telephony services to over 1.4 million residential and commercial customers, primarily in Texas, West Virginia, North Carolina, Oklahoma, Arkansas and […]

Continue

Dendreon Sells Royalty Interest

By Angela Sormani — 4 years ago

Dendreon Corporation has agreed to sell for $125 million in cash its royalty interest related to intellectual property licensed to Schering and associated with VICTRELIS, a treatment for chronic hepatitis C. The royalty interest was acquired by CPPIB Credit Investments, a wholly-owned subsidiary of CPP Investment Board. PRESS RELEASE Dendreon Corporation today announced that it […]

Continue